Preliminary analysis of cervical cancer immunotherapy
Loading...
Authors
Ma, Zhen
Zou, Xinxin
Yan, Zhaohua
Chen, Caiyun
Chen, Yumei
Fu, Aizhen
Issue Date
2022-10-26
Type
Article
Language
en_US
Keywords
Cervical Cancer , Immune Checkpoint , Vaccine , Immune Checkpoint Inhibitors
Alternative Title
Abstract
Cervical cancer is one of the most common gynecologically malignancies worldwide. Although vaccine and cervical cancer screening including human papillomavirus testing, cytology testing, and colposcopy have developed rapidly in recent years, effectively reducing cervical cancer mortality, cervical cancer remains a malignancy with higher female fatality rates worldwide and has a high risk for socioeconomically disadvantaged groups. The combination of platinum-paclitaxel and chemotherapy, possibly with the addition of bevacizumab, is currently the treatment of choice for advanced cervical cancer, but it only has remission purposes. Therefore, new therapeutic strategies are needed for both locally advanced and metastatic cervical cancer. Here, we make a preliminary analysis of cervical cancer immunotherapy.
Description
Citation
Ma, Z., Zou, X., Yan, Z., Chen, C., Chen, Y., & Fu, A. (2022). Preliminary Analysis of Cervical Cancer Immunotherapy. American journal of clinical oncology, 45(11), 486–490. https://doi.org/10.1097/COC.0000000000000950
Publisher
American Journal of Clinical Oncology